Equities Analysts Set Expectations for FibroGen Q4 Earnings

FibroGen, Inc (NASDAQ:FGEN) – William Blair increased their Q4 2025 earnings per share estimates for FibroGen in a research note issued on Tuesday, November 11th. William Blair analyst A. Hsieh now expects that the biopharmaceutical company will post earnings per share of ($4.82) for the quarter, up from their prior forecast of ($5.75). The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q1 2026 earnings at ($4.29) EPS, Q2 2026 earnings at ($4.25) EPS, Q3 2026 earnings at ($4.44) EPS, Q4 2026 earnings at ($4.40) EPS, FY2026 earnings at ($17.39) EPS and FY2027 earnings at ($14.65) EPS.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($1.61) EPS for the quarter, topping the consensus estimate of ($4.01) by $2.40. The company had revenue of $1.08 million during the quarter, compared to the consensus estimate of $1.64 million.

Several other analysts have also commented on FGEN. Wall Street Zen upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a report on Saturday, September 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroGen in a research report on Wednesday, October 8th. Finally, HC Wainwright restated a “buy” rating and set a $43.00 price target on shares of FibroGen in a research report on Wednesday, September 24th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, FibroGen presently has an average rating of “Hold” and an average target price of $43.00.

FibroGen Trading Down 0.7%

Shares of FGEN opened at $9.07 on Thursday. FibroGen has a 1-year low of $4.85 and a 1-year high of $21.94. The firm’s 50-day moving average price is $11.26 and its 200-day moving average price is $9.06. The firm has a market capitalization of $36.68 million, a price-to-earnings ratio of -23.87 and a beta of 0.75.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Connective Capital Management LLC purchased a new position in FibroGen during the second quarter valued at $80,000. Vanguard Group Inc. increased its holdings in shares of FibroGen by 3.5% during the third quarter. Vanguard Group Inc. now owns 184,244 shares of the biopharmaceutical company’s stock valued at $2,257,000 after acquiring an additional 6,204 shares in the last quarter. HighTower Advisors LLC raised its position in shares of FibroGen by 292.8% in the 1st quarter. HighTower Advisors LLC now owns 404,488 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 301,500 shares during the last quarter. Finally, Armistice Capital LLC raised its position in shares of FibroGen by 25.0% in the 1st quarter. Armistice Capital LLC now owns 8,500,000 shares of the biopharmaceutical company’s stock worth $2,634,000 after purchasing an additional 1,700,000 shares during the last quarter. Institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.